pubmed-article:1363515 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1363515 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
pubmed-article:1363515 | lifeskim:mentions | umls-concept:C1512310 | lld:lifeskim |
pubmed-article:1363515 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
pubmed-article:1363515 | lifeskim:mentions | umls-concept:C0011015 | lld:lifeskim |
pubmed-article:1363515 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
pubmed-article:1363515 | pubmed:issue | 6B | lld:pubmed |
pubmed-article:1363515 | pubmed:dateCreated | 1993-4-9 | lld:pubmed |
pubmed-article:1363515 | pubmed:abstractText | Cyclosporin A and verapamil are substrates for P-glycoprotein. Both agents are known to reverse multidrug resistance in cells overexpressing P-glycoprotein. In this investigation, we have examined the effects of cyclosporin A and verapamil on multidrug resistance in HL60/AR cells that lack P-glycoprotein. In addition, a correlation was sought between an alteration in plasma membrane potential as measured with cationic dye DIOC5 and overexpression of P-glycoprotein. HL60/AR cells accumulated 3 fold less daunorubicin than HL60 cells. The drug accumulation defect and drug resistance in HL60/AR cells were partially corrected by verapamil and buthionine sulfoximine. However, cyclosporin A had no detectable effect on daunorubicin accumulation or drug resistance in HL60/AR cells. The multidrug resistant P338/ADR cell line overexpressed P-glycoprotein and exhibited depolarization of plasma membrane when compared to its corresponding drug sensitive parental cell line. In contrast, HL60/AR cells lacked P-glycoprotein and plasma membrane potentials were similar to those of drug sensitive HL60 cells. These results suggest that [1] verapamil modulates daunorubicin transport by a mechanism independent of P-glycoprotein, [2] the mechanisms of reversal of multidrug resistance by verapamil and cyclosporin A are distinct, and [3] the plasma membrane depolarization in multidrug resistant cell lines that overexpress P-glycoprotein, as determined by DIOC5, may be due to an increased efflux of cationic dye by P-glycoprotein, rather than a true measurement of plasma membrane potential in multidrug resistant cells. | lld:pubmed |
pubmed-article:1363515 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:language | eng | lld:pubmed |
pubmed-article:1363515 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1363515 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1363515 | pubmed:issn | 0250-7005 | lld:pubmed |
pubmed-article:1363515 | pubmed:author | pubmed-author:GuptaSS | lld:pubmed |
pubmed-article:1363515 | pubmed:author | pubmed-author:GollapudiSS | lld:pubmed |
pubmed-article:1363515 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1363515 | pubmed:volume | 12 | lld:pubmed |
pubmed-article:1363515 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1363515 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1363515 | pubmed:pagination | 2127-32 | lld:pubmed |
pubmed-article:1363515 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:meshHeading | pubmed-meshheading:1363515-... | lld:pubmed |
pubmed-article:1363515 | pubmed:articleTitle | Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A. | lld:pubmed |
pubmed-article:1363515 | pubmed:affiliation | Division of Basic and Clinical Immunology, University of California, Irvine 92717. | lld:pubmed |
pubmed-article:1363515 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1363515 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1363515 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1363515 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1363515 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1363515 | lld:pubmed |